key: cord-0682652-ezbmr4qz
authors: Ni, Ming; Tian, Fang‐Bing; Xiang, Dan‐Dan; Yu, Bing
title: Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID‐19
date: 2020-06-09
journal: J Med Virol
DOI: 10.1002/jmv.26070
sha: 6706cc82cae7f522adfea576f69ea89314276742
doc_id: 682652
cord_uid: ezbmr4qz

To investigate the inflammatory factors and lymphocyte subsets which play an important role in the course of severe coronavirus disease 2019 (COVID‐19). A total of 27 patients with severe COVID‐19 who were admitted to Tongji Hospital in Wuhan from 1 to 21 February 2020 were recruited to the study. The characteristics of interleukin‐1β (IL‐1β), IL‐2 receptor (IL‐2R), IL‐6, IL‐8, IL‐10, tumor necrosis factor‐α (TNF)‐α, C‐reactive protein (CRP), serum ferritin and procalcitonin (PCT), and lymphocyte subsets of these patients were retrospectively compared before and after treatment. Before treatment, there was no significant difference in most inflammatory factors (IL‐1β, IL‐2R, IL‐6, IL‐8, IL‐10, CRP, and serum ferritin) between male and female patients. Levels of IL‐2R, IL‐6, TNF‐α, and CRP decreased significantly after treatment, followed by IL‐8, IL‐10, and PCT. Serum ferritin was increased in all patients before treatment but did not decrease significantly after treatment. IL‐1β was normal in most patients before treatment. Lymphopenia was common among these patients with severe COVID‐19. Analysis of lymphocyte subsets showed that CD4+ and particularly CD8+ T lymphocytes increased significantly after treatment. However, B lymphocytes and natural killer cells showed no significant changes after treatment. A pro‐inflammatory response and decreased level of T lymphocytes were associated with severe COVID‐19.

of proinflammatory cytokines and chemokines by immune effector cells. [7] [8] [9] [10] A cytokine storm triggers a violent attack by the immune system on the body, causing ARDS and multiple organ failure, and finally, leading to death. However, the main cytokines and chemokines involved in SARS-CoV and MERS-CoV infections differ. 7, 9 In COVID- 19 , it has been reported that patients being treated on intensive care units (ICU's) have higher plasma levels of interleukin-2 (IL-2), IL-7, IL-10, granulocyte-colony stimulating factor, interferon γ-inducible protein-10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1A, and tumor necrosis factor-α (TNF-α) compared to non-ICU patients. 2 Regarding other inflammatory factors, elevated IL-6, serum ferritin, and C-reactive protein (CRP) have been most commonly reported in patients with A cytokine storm is also associated with apoptosis of lymphocytes, leading to severe and transient lymphopenia. [12] [13] [14] [15] Lymphopenia is a common feature in patients with COVID-19 and might be a critical factor associated with disease severity and mortality. 2, 11, 16 One of the most recent reports has shown that the number of CD4 + and CD8 + T cells in the peripheral blood of a SARS-CoV-2-infected patient is significantly reduced, whereas the status of CD4 + and CD8 + T cells are excessive activation. 4 With increasing evidence on the key pathophysiological role of inflammatory factors in patients with COVID-19, immunomodulatory agents including corticosteroids, tocilizumab, and lucitanib have been considered for use in clinics. However, more laboratory and clinical evidence for their use are needed.

In this study, the characteristics of several inflammatory factors (IL-1β, IL-2 receptor (IL-2R), IL-6, IL-8, IL-10, TNF-α, CRP, serum ferritin, and procalcitonin [PCT] ) and lymphocyte subsets of 27 patients with severe COVID-19 patients were examined. We aimed to find appropriate targets for early intervention in patients with severe COVID-19 by comparing relevant laboratory indicators before and after treatment. We found that levels of IL-2R, IL-6, TNF-α, and CRP decreased significantly after corticosteroid therapy, followed by IL-8, IL-10, and PCT. Analysis of lymphocyte subsets showed that CD4 + and particularly CD8 + T lymphocytes increased significantly after treatment. However, B lymphocytes and natural killer (NK) cells showed no significant change after treatment. to attenuate lung inflammation and was given for no more than 1 week.

Blood laboratory tests and chest computed tomography were performed every 5 to 7 days. All 27 patients experienced improvements in their condition and as of 12 March 2020, eight male patients and nine female patients had been discharged from hospital. Blood samples of the patients were collected before treatment and after the condition improved significantly (ie, body temperature is normal for more than 3 days, respiratory symptoms improve obviously, and pulmonary imaging shows obvious absorption of inflammation).

This study received ethical approval from the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All participants gave written informed consent, and the study was carried out in accordance with the Declaration of Helsinki.

Levels of IL-1β, IL-2R, IL-8, IL-10, and TNF-α were measured using the IMMULITE 1000 Immunoassay system (Siemens Healthcare Diagnostics Products Limited). Levels of IL-6 and PCT were determined by electrochemiluminescence immunoassay (Cobas E601; Roche, Basel, Switzerland). CRP and serum ferritin were measured using latexenhanced immunoturbidimetry (Cobas 8000; Roche). All procedures were carried out according to the manufacturers' instructions.

The total number of lymphocytes in peripheral blood was counted using a hemocytometer. The percentages of CD3 + CD4 + CD8 − T lymphocytes, CD3 + CD4 − CD8 + T lymphocytes, CD3 − CD19 + B lymphocytes, and CD3 − CD16 + CD56 + lymphocytes among the total lymphocytes were The absolute numbers of different lymphocyte subsets were calculated by multiplying the percentages by the total lymphocyte count (CD4 + T lymphocytes count = total lymphocyte count × CD3 + CD4 + CD8 − %, CD8 + T lymphocytes count = total lymphocyte count × CD3 + CD4 − CD8 + %, B lymphocytes count = total lymphocyte count × CD3 − CD19 + %, and NK cell count = total lymphocyte count × CD3 − CD16 + CD56 + %).

All statistical analyses were performed using SPSS 22.0 (SPSS Inc, Chicago, IL). Data are expressed as mean ± standard deviation and were compared using the independent-samples t test. A P < .05 was considered statistically significant.

The median age of male and female patients was 61 and 60 years, respectively. Before treatment, lymphocyte subsets and inflammatory factors were evaluated (Table 1) . Lymphopenia was seen in 71.4% <5 pg/mL) was elevated only in three female patients, with a maximum of 12.2 pg/mL. There was no significant difference in IL-1β between male and female patients.

Inflammatory factors (IL-1β, IL-2R, IL-6, IL-8, IL-10, TNF-α, CRP, serum ferritin, and PCT) of the 27 patients were compared before and after treatment (Figure 1 ). After treatment, the respiratory symptoms of all patients were significantly relieved and most of the inflammatory factors were decreased from their pretreatment levels.

CRP, IL-6, TNF-α, and IL-2R were significantly decreased after treatment, followed by IL-8, IL-10, and PCT. IL-8 and IL-10 showed a pretreatment increase in fewer than 50% of the patients. Although PCT was elevated in 63% (17/27) of patients, the maximum level was only 0.41 ng/mL. Levels of IL-1β and serum ferritin did not change significantly after treatment. In fact, as described above, IL-1β levels were only elevated slightly in just three female patients. Serum ferritin, however, was elevated in all patients and did not decrease significantly after treatment. It is likely that this inflammatory factor decreased slower than the others.

Lymphopenia is very common in COVID-19 and is associated with disease severity. 2, 11 In this study, lymphopenia occurs in 70.4% Male (14) Female (13) IL-8, IL-10, TNF-α, CRP, PCT, and serum ferritin were measured before and after treatment. Data are expressed as mean ± SD and were compared using the independent-samples t test. COVID-19, coronavirus disease 2019; CRP, C-reactive protein; IL-1β, interleukin-1β; IL-2R, IL-2 receptor; PCT, procalcitonin; TNF-α, tumor necrosis factor-α. *P < .05, **P < .01, ***P < .001 patients, and the minimum was 27/µL. Lymphopenia improved after treatment in these patients. Among the lymphocyte subsets, the CD8 + T lymphocytes showed the most significant improvement, followed by CD4 + T lymphocytes. Overall, T lymphocytes and total lymphocytes levels improved significantly. However, the changes in B lymphocytes and NK cells were not significant ( Table 2 ).

The COVID-19 outbreak is a major challenge for clinicians. The disease pathogenesis remains to be fully characterized, and no phar- CRP plays an important role in innate immunity as an early defense mechanism against infections. Another inflammatory plasma marker that is extensively used in clinical practice is the ferritin. Unlike many bacterial infections, viral infections are commonly characterized by increased circulating ferritin concentrations. [29] [30] [31] [32] [33] In our study, CRP and serum ferritin were increased above normal levels in all patients with severe COVID-19, but only CRP decreased significantly after treatment. This is probably because serum ferritin levels decreased at a slower rate, but confirmation of this is required. PCT is known for its sensitivity to bacterial infections. 34 In our investigation, the PCT level was only slightly increased in patients with severe COVID-19, with the highest level less than 0.5 ng/mL, which does not support bacterial infection. PCT has been investigated for its ability to predict the development of inflammation.

However, the clinical effectiveness of this parameter is controversial. 35, 36 In our study, PCT levels decreased significantly after treatment.

In our study, CD4 + and particularly CD8 + T lymphocyte subtypes were reduced in patients with severe COVID-19, which is consistent with the general characteristics of viral pneumonia 37 and reflects the deficiency of the adaptive immune response. Previous research on viral infections has indicated that adaptive T cells, especially CD8 + T cells, provide broader and more lasting cross-reactive cellular immunity with fewer limitations of strain-specific restriction. 38 Histological examination of the lungs of patients who have died of COVID-19 has revealed interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes. 4 This finding has been correlated with lower CD4 + and CD8 + T cell counts in the peripheral blood samples of patients with severe COVID-19. In general, a significantly negative correlation has been reported between the number and function of both CD4 + and CD8 + T cells. 39 We found that proinflammatory factors were increased significantly in patients with severe COVID-19, which may be related to the decrease in T lymphocytes. After treatment, the number of T lymphocytes recovered alongside the decrease in proinflammatory factors.

The dynamic changes of lymphocytes function in this process need further study.

It had been reported that COVID-19 mostly affected men because immune genes are more expressed on the X chromosome. Although studies have provided evidence that cytokine storms and immunopathology can occur during pathogenic human coronaviruses infections, 5,6,8,9,11,20, Some limitations of this study should also be acknowledged. This was a retrospective, single-center, observational study, and unavoidable biases occurred when including participants. Furthermore, the sample size was very small. Despite these limitations, the study reflects the "real life" clinical situation.

In conclusion, a proinflammatory response, particularly the level of IL-2R, IL-6, TNF-α, and CRP, were associated with severe COVID-19.

The SARS-CoV-2 infection affect primarily T lymphocyte, particularly CD8 + T cells. The lymphocytes function in patients with severe COVID-19 need to be further clarified.

The authors would like to thank the patients who participated in this study, and the staff at Tongji Hospital for their assistance with study enrollment, data collection, and sample examination.

The authors declare that there are no conflict of interests.

MN researched literature and wrote the first draft of the manuscript. F-BT and D-DX collected the patients' clinical data.

BY designed the investigation, and reviewed and modified the manuscript. All authors have read and approved the final version of the manuscript.

The data used during the current report are available from the corresponding author on reasonable request.

This study received ethical approval from the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Written informed consent for publication of these clinical details was obtained from each patient. Copies of the consent form are available for review by the editor of this journal.

Bing Yu http://orcid.org/0000-0003-4365-2140

COVID-19: what is next for public health?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

The clinical pathology of severe acute respiratory syndrome (SARS): a report from China

Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates

Human immunopathogenesis of severe acute respiratory syndrome (SARS)

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

The mercurial nature of neutrophils: still an enigma in ARDS?

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo

Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways

Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans

Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections

Clinical characteristics of coronavirus disease 2019 in China

National Health Commission of China. 2020. Diagnosis and treatment program of new coronavirus pneumonia

Innate and adaptive T cells in influenza disease

Viruses detected by systematic multiplex polymerase chain reaction in adults with suspected community-acquired pneumonia attending emergency departments in France

Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome

How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

Mast cells contribute to coronavirus-induced inflammation: new antiinflammatory strategy

Clinical and immunological features of severe and moderate coronavirus disease 2019

TNF-mediated inflammatory disease

Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

IL-10: the master regulator of immunity to infection

IL-1beta/IL-6/ CRP and IL-18/ferritin: distinct inflammatory programs in infections

Ferritin levels predict severe dengue

Hyperferritinaemia in dengue virus infected patients is associated with immune activation and coagulation disturbances

Serum ferritin: past, present and future

Serum ferritin concentration predicts mortality in patients with hepatitis B virus-related acute on chronic liver failure

Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature

A comparison of the BISAP score and serum procalcitonin for predicting the severity of acute pancreatitis

Inflammatory mediators in the diagnosis and treatment of acute pancreatitis: pentraxin-3, procalcitonin and myeloperoxidase

Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score

Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge

Combination of lymphocyte number and function in evaluating host immunity

Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection

The immunobiology of SARS*

Cytokine storm and sepsis disease pathogenesis

Human coronavirus: host-pathogen interaction

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

SARS: systematic review of treatment effects

Corticosteroid therapy for critically Ill patients with Middle east respiratory syndrome

The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study

High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome

Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19